Estrogen replacement therapy in the patient treated for endometrial cancer

Wt, Creasman; Henderson, DeAnna; Hinshaw, Wanda; Clarke-Pearson, D.

doi:10.1016/0020-7292(87)90264-5

Cited by 93 publications

(99 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several retrospective trials of estrogen replacement after treatment of early-stage endometrial cancer have shown no increase in tumor recurrence or cancer-related deaths. [63][64][65] However, estrogen replacement trials in postmenopausal women with no history of malignancy have shown a significantly increased risk for breast cancer.…”

Section: Hormone Replacement Therapy For Endometrial Cancersmentioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Section: Hormone Replacement Therapy For Endometrial Cancersmentioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

“…A progressão anormal através de um endométrio normal para hiperplasia simples, hiperplasia complexa, atipia e carcinoma endometrial está associada à ação estrogênica sem oposição (16,17), e este é o principal argumento para a contra-indicação de terapia hormonal contendo estrogênios em mulheres com história de carcinoma de endométrio, mesmo na vigência da administração associada de progestogênios. Contudo, deve-se salientar que, em dois estudos retrospectivos que analisaram pacientes consideradas curadas após cirurgia para carcinoma endometrial em estádio I, com tumores bem diferenciados (grau I), não foi observada piora com o uso de terapia estrogênica (18,19). Com base nestes trabalhos (e embora as autoras não compartilhem desta posição, no momento atual), alguns autores não consideram contra-indicação absoluta o uso de estrogênios em pacientes com baixo risco endometrial que estejam curadas (20), desde que sejam informadas a respeito das incertezas quanto à segurança do seu uso.…”

Section: Carcinoma De Endométrio E Sangramento Vaginal Não Diagnosticadounclassified

Terapia hormonal na menopausa: quando não usar

Spritzer

Wender

2007

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOA menopausa corresponde à cessação permanente da menstruação, conseqüente à perda da função folicular ovariana ou à remoção cirúrgica dos ovários. A idade média para ocorrência da menopausa natural gira em torno de 50 anos. A deficiência estrogênica decorrente da menopausa está associada com sintomas vasomotores, atrofia urogenital, declínio cognitivo, assim como a um aumento no risco de doenças crônico-degenerativas, aterosclerose e doença cardiovascular, osteoporose e doença de Alzheimer. A estrogenioterapia permanece sendo o tratamento mais efetivo para o manejo dos sintomas vasomotores e atrofia urogenital. Em mulheres com útero presente, a progesterona natural ou os progestogênios devem ser associados ao tratamento com estradiol para antagonizar os efeitos proliferativos deste hormônio sobre o endométrio e anular o risco de hiperplasia/carcinoma endometrial. Por outro lado, em determinadas condições clínicas, a terapia hormonal não é recomendada ou é mesmo contra-indicada. Neste artigo, focalizamos criticamente essas situações clínicas em que não se deve indicar a terapia hormonal na menopausa. Menopause is defined as the permanent cessation of menses, as a result of the loss of ovarian follicular function or of surgical removal of ovaries. The mean age for occurrence of natural menopause is around 50 years. Estrogen deficiency has been associated with vasomotor symptoms, urogenital atrophy, and cognitive impairment, as well as increased risk of chronic degenerative diseases such as osteoporosis and Alzheimer's disease. Estrogen therapy remains the most effective treatment for the management of vasomotor symptoms and urogenital atrophy. Progesterone or progestins should be added to estrogen treatment in women with uterus, in order to antagonize the estrogen-induced endometrial proliferation. In turn, in specific clinical conditions hormone therapy is not recommended. In the present article, the authors critically focus these clinical conditions in which hormone therapy should not be used.

show abstract

“…Clinical experience and research do not substantiate the common belief that pregnancy shortly before, during or soon after the diagnosis of cancer worsens the prognosis, or increases the chance of recurrence, 216,217 with the exception of trophoblastic disease. Despite the lack of scientific evidence, the fear that pregnancy could cause a recurrence is common among women with cancer, regardless of the cancer type.…”

Section: The Effect Of Pregnancy On Prognosis or Recurrencesmentioning

confidence: 99%

Broken doctor–patient relationships: why won't they listen?

Jefford

Zalcberg

2014

Medical Journal of Australia

View full text Add to dashboard Cite

Every user of this rescinded publication acknowledges that the information contained in it may not be accurate, complete or of relevance to the user's purposes. The user undertakes the responsibility for assessing the accuracy, completeness and relevance of the contents of this rescinded publication, including seeking independent verification of information sought to be relied upon for the user's purposes.Every user of this rescinded publication is responsible for ensuring that each printed version contains this disclaimer notice, including the date of recision and the date of downloading the archived Internet version. This work is copyright.Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from National Breast Cancer Centre. Requests and enquiries concerning reproduction and rights should be addressed to the Copyright Office, National Breast Cancer Centre, Locked Bag 16, Camperdown NSW 1450, Australia.Website:www.nbcc.org.au Email: directorate@nbcc.org.au These guidelines were approved by the National Health and Medical Research Council at its 147th Session on 10 April 2003, under section 14A of the National Health and Medical Research Council Act 1992.Approval for the guidelines by NHMRC is granted for a period not exceeding five years, at which date the approval expires.The NHMRC expects that all guidelines will be reviewed no less than once every five years. Readers should check with the National Breast Cancer Centre for any reviews or updates of these guidelines. RESCINDEDThe strategic intent of the NHMRC is to provide leadership and work with other relevant organisations to improve the health of all Australians by:• fostering and supporting a high quality and internationally recognised research base; • providing evidence based advice; • applying research evidence to health issues thus translating research into better health practice and outcomes; and • promoting informed debate on health and medical research, health ethics and related issues.This document is a general guide to appropriate practice, to be followed subject to the clinician's judgement and the patient's preference in each individual case.The guidelines are designed to provide information to assist decision-making and are based on the best evidence available at the time of publication. C O N T E N T S L I S T O F TA B L E S L I S T O F F I G U R E S F O R E W O R DOptimal care of the patient with cancer incorporates effective physical and psychological care.There are currently several clinical practice guidelines available documenting evidence-based information and treatment recommendations for the physical care of people with cancer, many of which are also available in consumer versions. Some of these treatment guidelines include chapters devoted to psychosocial care.People with cancer suffer significant emotional morbidity. In addition to the distress, fear and grief consequent upon diagnosis, up to 30% experience clinically significant anxiety disorde...

show abstract

Estrogen replacement therapy in the patient treated for endometrial cancer

Cited by 93 publications

References 0 publications

Uterine Neoplasms

Uterine Neoplasms

Terapia hormonal na menopausa: quando não usar

Broken doctor–patient relationships: why won't they listen?

Contact Info

Product

Resources

About